Healthcare provider profile · identity verified

Monita Singh

Internal Medicine · BIRMINGHAM, AL · NPI 1578645776

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	513	162
Amlodipine Besylate	Amlodipine Besylate	415	124
Losartan Potassium	Losartan Potassium	342	100
Levothyroxine Sodium	Levothyroxine Sodium	328	106
Lisinopril	Lisinopril	277	84
Metoprolol Succinate	Metoprolol Succinate	252	72
Trazodone Hcl	Trazodone Hcl	226	74
Omeprazole	Omeprazole	203	84
Gabapentin	Gabapentin	183	78
Rosuvastatin Calcium	Rosuvastatin Calcium	182	62
Metformin Hcl	Metformin Hcl	167	53
Pravastatin Sodium	Pravastatin Sodium	154	54
Sertraline Hcl	Sertraline Hcl	148	44
Ozempic	Semaglutide	146	30
Famotidine	Famotidine	134	42
Pantoprazole Sodium	Pantoprazole Sodium	116	39
Duloxetine Hcl	Duloxetine Hcl	113	33
Hydrochlorothiazide	Hydrochlorothiazide	113	40
Eliquis	Apixaban	110	23
Bupropion Xl	Bupropion Hcl	109	31
Carvedilol	Carvedilol	104	33
Jardiance	Empagliflozin	102	32
Montelukast Sodium	Montelukast Sodium	100	34
Estradiol	Estradiol	94	42
Venlafaxine Hcl Er	Venlafaxine Hcl	89	20
Atenolol	Atenolol	87	31
Potassium Chloride	Potassium Chloride	83	30
Furosemide	Furosemide	81	28
Fluoxetine Hcl	Fluoxetine Hcl	80	21
Escitalopram Oxalate	Escitalopram Oxalate	77	24
Alprazolam	Alprazolam	72	24
Simvastatin	Simvastatin	72	21
Valsartan	Valsartan	70	23
Tramadol Hcl	Tramadol Hcl	68	26
Fluticasone Propionate	Fluticasone Propionate	65	31
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	64	21
Tamsulosin Hcl	Tamsulosin Hcl	62	21
Donepezil Hcl	Donepezil Hcl	61	19
Propranolol Hcl	Propranolol Hcl	60	20
Chlorthalidone	Chlorthalidone	59	20
Azithromycin	Azithromycin	58	43
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	58	15
Metoprolol Tartrate	Metoprolol Tartrate	56	19
Pregabalin	Pregabalin	55	15
Spironolactone	Spironolactone	55	24
Zolpidem Tartrate	Zolpidem Tartrate	55	20
Allopurinol	Allopurinol	54	19
Citalopram Hbr	Citalopram Hydrobromide	53	24
Metformin Hcl Er	Metformin Hcl	52	15
Clonazepam	Clonazepam	50	16
Glipizide Er	Glipizide	50	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	49	28
Mirtazapine	Mirtazapine	44	14
Mounjaro	Tirzepatide	44	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	42	suppressed
Buspirone Hcl	Buspirone Hcl	41	12
Methocarbamol	Methocarbamol	40	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	39	13
Synthroid	Levothyroxine Sodium	39	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	38	14
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	37	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	36	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	35	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	34	12
Paroxetine Hcl	Paroxetine Hcl	34	11
Meloxicam	Meloxicam	32	18
Valacyclovir	Valacyclovir Hcl	32	14
Myrbetriq	Mirabegron	31	suppressed
Alendronate Sodium	Alendronate Sodium	29	11
Ezetimibe	Ezetimibe	28	suppressed
Januvia	Sitagliptin Phosphate	28	suppressed
Memantine Hcl	Memantine Hcl	28	suppressed
Lorazepam	Lorazepam	25	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	25	22
Prednisone	Prednisone	25	12
Trulicity	Dulaglutide	25	suppressed
Azelastine Hcl	Azelastine Hcl	24	suppressed
Benazepril Hcl	Benazepril Hcl	24	suppressed
Warfarin Sodium	Warfarin Sodium	24	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	23	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	22	suppressed
Baclofen	Baclofen	22	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	21	suppressed
Raloxifene Hcl	Raloxifene Hcl	21	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	20	19
Fluconazole	Fluconazole	20	11
Hydralazine Hcl	Hydralazine Hcl	19	suppressed
Potassium Citrate Er	Potassium Citrate	19	suppressed
Risedronate Sodium	Risedronate Sodium	19	suppressed
Tresiba Flextouch U-100	Insulin Degludec	19	suppressed
Entresto	Sacubitril/Valsartan	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Incruse Ellipta	Umeclidinium Bromide	17	suppressed
Clopidogrel	Clopidogrel Bisulfate	15	suppressed
Lamotrigine	Lamotrigine	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Celecoxib	Celecoxib	14	suppressed
Creon	Lipase/Protease/Amylase	14	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Meclizine Hcl	Meclizine Hcl	14	suppressed
Methylphenidate Er (La)	Methylphenidate Hcl	14	suppressed
Naproxen	Naproxen	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	13
Lovastatin	Lovastatin	13	suppressed
Prazosin Hcl	Prazosin Hcl	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Scopolamine	Scopolamine	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	11
Ondansetron Odt	Ondansetron	12	suppressed
Telmisartan	Telmisartan	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Finasteride	Finasteride	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Paroxetine Cr	Paroxetine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error